Condition: Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) · AML (Acute Myelogenous Leukemia) · Myeloma Multiple · Sponsor: Tianjin Medical University General Hospital
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
This description comes directly from the study's public registry record.
Rong Fu · +86 12260817111 · yhwhao@126.com
Always discuss trial participation with your own doctor first.
| TianJin China. TianJin Medical University General | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06911710